NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

RhEumatoid Arthritis MEDIcation Adherence

RecruitingNA

Sponsor: Hospices Civils de Lyon

Conditions: Rheumatoid Arthritis

Interventions: Pharmaceutical care in multiprofessional collaboration

Countries: France

Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients. Main objective: To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration. Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)). METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patient with diagnosed rheumatoid arthritis (RA),
* Patient, male or female, aged 18 or over,
* Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge
* Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD),
* Autonomous patient in the management of his drug treatment,
* Patient understanding and speaking French,
* Patient affiliated to the French general national health insurance or similar,
* Patient having given his free, informed and signed consent.

Exclusion Criteria:

* Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study,
* Patient whose regular pharmacy is currently treating another patient.
* Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator),
* Patient whose management of his drug treatment at home is carried out exclusively by a carer,
* Patient participating in another research that may interfere (investigator's judgement) with the results of the present study,
* Adult patient protected under the terms of the law (Public Health Code),
* Patient not fit to carry out the follow-up, according to the judgment of the investigator,
* Pregnant or breastfeeding women.

Locations (2)

Pierre-Bénite, Lyon, France
Lyon, France